- Report
- December 2023
- 145 Pages
Global
From €5709EUR$5,950USD£4,937GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,148GBP
- Report
- February 2022
- 180 Pages
Global
From €3056EUR$3,185USD£2,643GBP
€4366EUR$4,550USD£3,775GBP
- Report
- April 2023
- 85 Pages
Global
From €3500EUR$3,908USD£3,132GBP
- Report
- January 2021
- 142 Pages
China, Global
From €3000EUR$3,349USD£2,685GBP
- Report
- May 2024
- 50 Pages
Global
From €2543EUR$2,650USD£2,199GBP
- Report
- May 2024
- 50 Pages
Global
From €2543EUR$2,650USD£2,199GBP
- Book
- October 2019
- 720 Pages
Cilastatin is an antibiotic used in combination with other antibiotics to treat a variety of bacterial infections. It is a prodrug, meaning it is inactive until it is metabolized in the body. Cilastatin is used in combination with imipenem to treat serious infections caused by susceptible bacteria. It is also used to reduce the risk of kidney damage caused by imipenem. Cilastatin is available in both oral and intravenous formulations.
Cilastatin is used in combination with other antibiotics to treat a variety of bacterial infections, including pneumonia, urinary tract infections, and skin and soft tissue infections. It is also used to reduce the risk of kidney damage caused by imipenem. Cilastatin is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea.
The cilastatin market is a niche market, with a limited number of manufacturers. Some of the companies in the market include Merck & Co., Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. Show Less Read more